Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Cerevel Therapeutics Holdings Inc market cap is $8.19B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Cerevel Therapeutics Holdings Inc 52 week high is $44.99 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Cerevel Therapeutics Holdings Inc 52 week low is $19.59 as of November 22, 2026.
Cerevel Therapeutics Holdings Inc stock price today is $44.97.
Cerevel Therapeutics Holdings Inc stock price yesterday was $44.63.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Cerevel Therapeutics Holdings Inc's P/E ratio is -16.46.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Cerevel Therapeutics Holdings Inc P/B ratio is 14.4878.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Cerevel Therapeutics Holdings Inc 50-day moving average is $42.09.